Adial Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Rhea-AI Summary

Adial Pharmaceuticals, focused on addiction treatments, announced that CEO William Stilley will present at the H.C. Wainwright 23^rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be available on-demand starting September 13 at 7:00 AM Eastern Time. Adial's lead drug, AD04, is being studied in its ONWARD™ Phase 3 trial for Alcohol Use Disorder (AUD) targeting specific genetic profiles, following promising Phase 2b results. The company also explores treatments for other addictions and related disorders.

CHARLOTTESVILLE, Va., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that William Stilley, Chief Executive Officer of Adial Pharmaceuticals, will be presenting at the H.C. Wainwright 23^rd Annual Global Investment Conference being held virtually between September 13-15, 2021.

Adial Pharmaceutical’s presentation will be available on-demand to registered attendees via the conference platform beginning Monday, September 13, 2021 at 7:00 AM Eastern Time.

The webcast can be accessed here and on the investor relations section of Adial Pharmaceutical’s website at https://ir.adialpharma.com/. Management will also be participating in one-on-one meetings with qualified members of the investor community throughout the conference.

About Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company’s landmark ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test. A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. The Company is also developing adenosine analogs for the treatment of pain and other disorders. Additional information is available at www.adialpharma.com.

Contact:
Crescendo Communications, LLC          
David Waldman / Natalya Rudman
Tel: 212-671-1021
Email: adil@crescendo-ir.com

FAQ

When is Adial Pharmaceuticals presenting at the H.C. Wainwright Conference?

Adial Pharmaceuticals will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021.

What time will Adial's presentation be available?

Adial's presentation will be available on-demand starting September 13, 2021, at 7:00 AM Eastern Time.

What is Adial Pharmaceuticals' lead drug?

Adial Pharmaceuticals' lead drug is AD04, which is being investigated for Alcohol Use Disorder (AUD).

What trials is AD04 currently involved in?

AD04 is currently undergoing the ONWARD™ pivotal Phase 3 clinical trial for the treatment of Alcohol Use Disorder.

What were the results of the Phase 2b trial for AD04?

The Phase 2b trial for AD04 showed statistically significant results in reducing drinking frequency, quantity, and heavy drinking.

What other conditions might AD04 potentially treat?

In addition to Alcohol Use Disorder, AD04 may also have potential for treating Opioid Use Disorder, gambling, and obesity.

How can I access the webcast of Adial's presentation?

The webcast can be accessed on the conference platform or the investor relations section of Adial Pharmaceuticals' website.